Ahmed El-Modir (@elmodir) profile picture
Birmingham/UK
Joined August 2009
Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)
Ahmed El-Modir retweeted
🚨 55.6% response rate in heavily pretreated ovarian cancer! Could Rinatabart sesutecan (Rina-S) be the next major ADC in gynecologic oncology? 📌 RAINFOL-01 | Phase 1/2 | IJGC 2026 An FRα-directed ADC carrying an exatecan payload, evaluated without FRα-based patient selection. 🔹 Ovarian cancer (120 mg/m²) • ORR: 55.6%, including 4 complete responses • Median DoR: Not reached 🔹 Endometrial cancer • ORR: 50% (100 mg/m²) • ORR: 44.1% (120 mg/m²) • Median DoR: 9.8–13.5 months ⚠️ Significant grade ≥3 cytopenias, particularly neutropenia and anemia. 💡 My take: Promising activity across FRα expression levels, but small, noncomparative cohorts. Phase 3 confirmation is essential. @oncoalert #OvarianCancer #EndometrialCancer #ADC Full paper link in comment below ⬇️
1
4
14
1,465
Ahmed El-Modir retweeted
NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer. Urinary tumor DNA in #MIBC from NIAGARA. @MichvdHeijden @NKI_nl joins @ERPlimackMD @FoxChaseCancer to discuss utDNA and ctDNA with perioperative durvalumab. pCR was 72% if utDNA-negative vs 18% if positive. #WatchNow on UroToday > bit.ly/4eCoewi
5
6
876
Ahmed El-Modir retweeted
Cardiovascular Risk Assessment and Management in #ProstateCancer Survivorship. Cardiovascular care is #ProstateCancer survivorship care. @ravi_b_parikh @WinshipAtEmory notes only 68% of VA patients received comprehensive CV risk assessment and outlines a structured approach starting at the ADT conversation. @PCFnews #WatchNow on UroToday > bit.ly/3VJjGhh
2
9
813
Ahmed El-Modir retweeted
ADT Class and Cardiovascular Risk: A Large Retrospective Analysis in Prostate Cancer. Does ADT class affect cardiovascular risk in #ProstateCancer? @OncHahn @UTMDAnderson joins @neerajaiims @DanaFarber to discuss a large real-world analysis of major adverse cardiac events in men receiving androgen deprivation therapy. #WatchNow on UroToday > bit.ly/4ykeNIZ
1
9
16
1,407
Ahmed El-Modir retweeted
#ProstateCancer Highlights and Clinical Implications. @CaPsurvivorship, @DanaFarber, and @zklaassen_md review the DASL-HiCaP, PROTEUS, CAPItello-281, and JNJ-6143 studies from #ESMO26 in this conversation on UroToday > bit.ly/4iwbatD
8
16
1,306
Ahmed El-Modir retweeted
Optimizing Therapy for Locally Advanced #ProstateCancer. Presented by @BarbaraJereczek. #ESMO26 written coverage by @zklaassen_md > bit.ly/4z7fiav #RadOnc #GUOnc @myESMO
15
1
44
3,776
Ahmed El-Modir retweeted
Management of #mCRPC: Personalized Treatment Selection and Sequencing. Presented by Dr. Deborah Mukherji, MBBS, FRCP. #ESMO26 written coverage by @zklaassen_md > bit.ly/4eSjvGU #ProstateCancer #PrecisionOncology @myESMO
16
28
1,413
Ahmed El-Modir retweeted
LuCAB: Phase I/II Trial of Cabazitaxel + 177Lu-PSMA in mCRPC. Presented by @LouiseKostos @PeterMacCC. #ESMO26 written coverage by @rksayyid > bit.ly/4zULptV #ProstateCancer #mCRPC #ClinicalTrials @myESMO
1
8
15
980
Ahmed El-Modir retweeted
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) nej.md/4BiCvbk #ESMO26 | @myESMO
1
38
5
97
20,752
Ahmed El-Modir retweeted
🚨 PD-L1 ≥50% NSCLC: Is pembrolizumab alone enough? 🔥 PERSEE Phase III | #ESMO26 Pembrolizumab + chemotherapy vs pembrolizumab alone: 📊 PFS: 16.1 vs 6.9 months (HR 0.56; p<0.001) 📊 OS: 50.2 vs 29.9 months (HR 0.77; CI crosses 1) 🎯 PFS benefit persisted even with PD-L1 ≥90%. 💡 Verdict: Strong PFS benefit, but OS advantage remains unproven. @myesmo @ESMO_open @ASCO @oncoalert Full paper link in comment below ⬇️
🚨 PD-L1 ≥50% in NSCLC: Is pembrolizumab alone enough? 🔥 PERSEE Phase III | #ESMO26 Concomitant publication in Annals of Oncology. Pembrolizumab + chemotherapy vs pembrolizumab alone: 📊 PFS: 16.1 vs 6.9 months (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Grade ≥3 toxicity: 54% vs 19% OS: 50.2 vs 29.9 months (HR 0.77), not statistically significant. 💡 Verdict: Better disease control, but at a substantial toxicity cost. Is PD-L1 ≥50% alone sufficient to omit chemotherapy? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #LungCancer
6
26
1,358
Ahmed El-Modir retweeted
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu #ESMO26 | @myESMO
3
33
3
116
18,537
Ahmed El-Modir retweeted
Original Article: Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (phase 3 DeLLphi-305 trial) nej.md/4iveIgW #ESMO26 | @myESMO
29
1
91
13,934
Ahmed El-Modir retweeted
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10 Trials 1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC 2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC 3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors 4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC 5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression 6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel 7.SARON | Consolidation RT in oligometastatic NSCLC 8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50% 9.DeLLphi-304 | Long-term survival with tarlatamab 10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1. Which trial could have the biggest impact on lung cancer treatment? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #LungCancer #Oncology
🤖 Made with AI
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open
28
3
95
15,805
Ahmed El-Modir retweeted
Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW @myESMO
9
149
32
506
76,786
Ahmed El-Modir retweeted
Surreal footage. Total solar eclipse in Spain.
124
1,418
70
9,774
484,935
Ahmed El-Modir retweeted
Denosumab vs Zoledronic Acid in Bone Metastases • 3 pivotal phase III trials • >5,700 patients in pooled analysis • Modest reduction in skeletal-related events with denosumab (HR 0.83) • No overall survival benefit • More hypocalcemia with denosumab • Less renal toxicity and no dose adjustment Choose based on efficacy, renal function, convenience, cost, and patient preference. #Oncology #MedTwitter #BoneMetastases #BreastCancer #ProstateCancer #MVOnco
18
38
1,713